| 000 | 01629 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250516083752.0 | ||
| 264 | 0 | _c20120718 | |
| 008 | 201207s 0 0 eng d | ||
| 022 | _a1365-2796 | ||
| 024 | 7 |
_a10.1111/j.1365-2796.2012.02541.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTripodi, A | |
| 245 | 0 | 0 |
_aNew anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation. _h[electronic resource] |
| 260 |
_bJournal of internal medicine _cJun 2012 |
||
| 300 |
_a554-65 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAnticoagulants _xtherapeutic use |
| 650 | 0 | 4 |
_aAtrial Fibrillation _xcomplications |
| 650 | 0 | 4 |
_aBenzimidazoles _xpharmacology |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aClinical Trials, Phase III as Topic |
| 650 | 0 | 4 | _aDabigatran |
| 650 | 0 | 4 | _aDrugs, Investigational |
| 650 | 0 | 4 |
_aHeparin _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInternational Normalized Ratio |
| 650 | 0 | 4 |
_aMorpholines _xpharmacology |
| 650 | 0 | 4 |
_aPyrazoles _xpharmacology |
| 650 | 0 | 4 |
_aPyridones _xpharmacology |
| 650 | 0 | 4 | _aRivaroxaban |
| 650 | 0 | 4 |
_aStroke _xetiology |
| 650 | 0 | 4 |
_aThiophenes _xpharmacology |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVenous Thromboembolism _xetiology |
| 650 | 0 | 4 |
_aVitamin K _xantagonists & inhibitors |
| 650 | 0 | 4 |
_abeta-Alanine _xanalogs & derivatives |
| 700 | 1 | _aPalareti, G | |
| 773 | 0 |
_tJournal of internal medicine _gvol. 271 _gno. 6 _gp. 554-65 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2796.2012.02541.x _zAvailable from publisher's website |
| 999 |
_c21646919 _d21646919 |
||